Home > Riviste > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Fascicoli precedenti > The Quarterly Journal of Nuclear Medicine 2001 June;45(2) > The Quarterly Journal of Nuclear Medicine 2001 June;45(2):189-200

ULTIMO FASCICOLO
 

JOURNAL TOOLS

Opzioni di pubblicazione
eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Estratti
Permessi
Share

 

  RADIOPHARMACOLOGY 

The Quarterly Journal of Nuclear Medicine 2001 June;45(2):189-200

Copyright © 2009 EDIZIONI MINERVA MEDICA

lingua: Inglese

Imaging tumors with peptide-based radioligands

Behr T. M., Gotthardt M., Barth A., Béhé M.

From the Department of Nuclear Medicine of the Philipps-University of Marburg, Marburg, Germany


PDF


Reg­u­la­tory pep­tides are ­small, ­readily dif­fus­able and ­potent nat­ural sub­stances ­with a ­wide spec­trum of ­receptor-medi­ated ­actions in ­humans. ­High ­affinity recep­tors for ­these pep­tides are (­over-) ­expressed in ­many neo­plasms, and ­these recep­tors may rep­re­sent, there­fore, new molec­ular tar­gets for ­cancer diag­nosis and ­therapy. ­This ­review ­aims to ­give an over­view of the pep­tide-­based radio­phar­ma­ceu­ti­cals ­which are pres­ently ­already com­mer­cially avail­able or ­which are in ­advanced ­stages of ­their clin­ical ­testing so ­that ­their ­broader avail­ability is antic­i­pated ­soon. Phys­io­log­i­cally, ­these pep­tides ­bind to and act ­through G pro­tein-cou­pled recep­tors in the ­cell mem­brane. His­tor­i­cally, som­a­tos­tatin ana­logs are the ­first ­class of ­receptor ­binding pep­tides ­having ­gained clin­ical appli­ca­tion. 111In-­DTPA-[D-Phe1]-octre­o­tide is the ­first and ­only radio­pep­tide ­which has ­obtained reg­u­la­tory ­approval in ­Europe and the ­United ­States to ­date. Exten­sive clin­ical ­studies ­involving sev­eral thou­sands of ­patients ­have ­shown ­that the ­major clin­ical appli­ca­tion of som­a­tos­tatin ­receptor scin­tig­raphy is the detec­tion and the ­staging of gas­troen­te­rop­an­creatic neu­ro­en­do­crine ­tumors (car­ci­noids). In ­these ­tumors, octre­o­tide scin­tig­raphy is ­superior to any ­other ­staging ­method. How­ever, its sen­si­tivity and accu­racy in ­other, ­more fre­quent neo­plasms is lim­ited. Radio­lab­eled vasoac­tive intes­tinal pep­tide (VIP) has ­been ­shown to vis­u­alize the ­majority of gas­troin­tes­tinal adeno-­car­cin­omas, as ­well as ­some neu­ro­en­do­crine ­tumors, ­including insu­lin­omas (the ­latter ­being ­often ­missed by som­a­tos­tatin ­receptor scin­tig­raphy). Due to the out­standing diag­nostic accu­racy of the pen­ta­gas­trin ­test in ­detecting the pres­ence, per­sis­tence, or recur­rence of medul­lary thy­roid ­cancer (MTC), we pos­tu­lated the expres­sion of the cor­re­sponding (i.e. chol­e­cys­tok­inin [CCK-] -B) ­receptor ­type in ­human MTC. ­This ­receptor is ­also ­widely ­expressed on ­human ­small-­cell ­lung ­cancer. ­Indeed, 111In-­labeled ­DTPA deriv­a­tives of gas­trin ­showed excel­lent tar­geting of CCK-B ­receptor ­expressing tis­sues in ani­mals and ­patients. A ­variety of fur­ther pep­tide-­based radio­lig­ands, e.g. ­among ­many ­others, gas­trin-­releasing pep­tide/bom­besin, neu­ro­tensin, sub­stance-P, pan-som­a­tos­tatin (som­a­tos­tatin deriv­a­tives ­which ­bind to all ­five ­receptor sub­types) or glu­cagon-­like pep­tide-1 (glp-1) ana­logs (the ­latter for the spe­cific detec­tion of insu­lin­omas), is cur­rently ­under devel­op­ment. Sum­mar­izing, radio­lab­eled reg­u­la­tory pep­tides ­have ­opened new hori­zons in ­nuclear ­oncology for diag­nosis (and poten­tial ­internal radio­nu­clide ­therapy). ­Future ­work ­will prob­ably ­reveal a mul­ti­tude of ­novel poten­tially clin­i­cally ­useful pep­tide-­based radio­lig­ands.

inizio pagina